Zepbound review: is it worth it?
Zepbound (tirzepatide) is a dual GIP/GLP-1 agonist FDA-approved for chronic weight management and OSA with obesity.
The most effective FDA-approved weight-loss drug to date
If you qualify on BMI and can secure coverage or self-pay pricing, Zepbound has delivered the largest average weight loss of any approved obesity medication in head-to-head data, and it is the only GLP-1-based drug also cleared for moderate-to-severe sleep apnea. The trade-offs are real: it is an indefinite weekly injection, often causes nausea, and can cost hundreds to over a thousand dollars a month depending on your coverage. For many eligible adults who have struggled with diet and exercise alone, the efficacy is hard to beat, but only a licensed clinician can decide whether it is appropriate for you.
Check PriceFrom $1349/mo
Pros
- ✓Most effective FDA-approved weight-loss medication to date, with up to about 22.5% average body-weight loss at the 15 mg dose in SURMOUNT-1
- ✓Demonstrated head-to-head superiority over Wegovy (20.2% vs 13.7%) in the SURMOUNT-5 NEJM trial
- ✓Convenient once-weekly injection with a flexible dosing window (can be taken up to 4 days late)
- ✓Dual GIP/GLP-1 mechanism, plus a second FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity
- ✓More affordable paths than the list price: Lilly self-pay vials ($299-$449/month), a $25 commercial savings card, and new Medicare coverage for obesity rolling out in 2026
Cons
- ✕Common gastrointestinal side effects (nausea, diarrhea, vomiting, constipation), especially during dose increases, which lead some people to stop treatment
- ✕Expensive without good coverage; the list price is over $1,000/month and self-pay can run hundreds per month indefinitely, and coverage still varies by plan
- ✕Effects are not permanent: weight regain is common after stopping, making it a likely long-term commitment
- ✕Carries an FDA boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2
- ✕Prescription-only with required dose titration, plus rare but serious risks like pancreatitis, gallbladder disease, and acute kidney injury
How it works
Zepbound's active drug, tirzepatide, is a once-weekly injection that activates two gut-hormone receptors at once: GLP-1 and GIP. This "dual agonist" design is what sets it apart from GLP-1-only drugs like Wegovy. By mimicking these hormones, it curbs appetite, increases fullness, and slows how fast the stomach empties, so most people eat less and feel satisfied longer. It also improves how the body releases insulin and handles blood sugar. The result is sustained calorie reduction without the constant hunger that derails many diets.
Active ingredient: Tirzepatide
Effectiveness
In the pivotal 72-week SURMOUNT-1 trial (2,539 adults with obesity or overweight, without type 2 diabetes; published in the New England Journal of Medicine in 2022), tirzepatide produced average body-weight reductions of about 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, versus roughly 2.4% with placebo. In the head-to-head SURMOUNT-5 trial (751 participants, 72 weeks, NEJM 2025), Zepbound beat Wegovy (semaglutide) with an average 20.2% weight loss versus 13.7%, a 47% greater relative reduction; about 31.6% of Zepbound users lost at least 25% of their body weight versus 16.1% on Wegovy. Zepbound is also FDA-approved (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity, where the SURMOUNT-OSA program showed clinically meaningful reductions in the apnea-hypopnea index versus placebo. Individual results vary with dose, diet, and activity.
Side effects
The most common side effects are gastrointestinal and tend to appear during dose increases: nausea (reported in roughly 25-30% of users across the pivotal trials, and as high as the mid-30s in some studies), diarrhea, vomiting, constipation, abdominal pain, indigestion, and fatigue or injection-site reactions. These are usually mild-to-moderate and ease over time with slow titration, though they lead a small percentage of people to stop treatment. Less common but serious risks include pancreatitis (severe persistent abdominal pain), gallbladder problems including gallstones, acute kidney injury (often from dehydration due to vomiting or diarrhea), severe allergic reactions, and low blood sugar when combined with insulin or sulfonylureas. Zepbound carries an FDA boxed warning for thyroid C-cell tumors seen in rodent studies; whether it causes them in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Seek care promptly for severe stomach pain, signs of an allergic reaction, or vision changes.
Cost
Starts at $1349/mo from Eli Lilly.
As of 2026, Zepbound's retail list price is roughly $1,086 per month for the pen, but few people pay that. Through Lilly's self-pay program (LillyDirect), single-dose vials run about $299/month for 2.5 mg, $399/month for 5 mg, and $449/month for 7.5 mg and higher strengths; for the higher doses you generally must refill within 45 days to keep that pricing, and it cannot be combined with insurance. If you have commercial insurance that covers Zepbound, Lilly's savings card can drop your copay to as little as $25/month (with a monthly and annual cap on total savings). Coverage is improving: many commercial plans now cover it for weight loss, and under a November 2025 agreement between Lilly and the U.S. government, Medicare is set to begin covering Zepbound for obesity with eligible beneficiaries paying no more than about $50/month, with phased rollout starting in 2026 and expanded Medicaid options for states. Coverage still varies by plan, so confirm your own benefits and current pricing before starting. Budget for ongoing monthly cost since it is a long-term medication.
Is it worth it?
Zepbound is the strongest weight-loss medication the FDA has approved to date, with demonstrated superiority over Wegovy in a head-to-head trial and a second indication for obstructive sleep apnea. It works only while you keep taking it, GI side effects are common early on, and affordability depends heavily on insurance, new government-coverage changes, or Lilly's self-pay vials. Discuss eligibility and the thyroid-tumor boxed warning with a clinician before starting. This is general information, not medical advice.
Frequently asked questions
How much weight can you lose on Zepbound?
In the 72-week SURMOUNT-1 trial, adults lost an average of about 16% of body weight at the 5 mg dose, 21.4% at 10 mg, and 22.5% at 15 mg, compared with roughly 2.4% on placebo. Individual results vary and depend on dose, diet, and activity. This is general information, not medical advice.
Is Zepbound better than Wegovy?
In the head-to-head SURMOUNT-5 trial, Zepbound produced greater average weight loss than Wegovy (20.2% vs 13.7% over 72 weeks), a 47% greater relative reduction. Zepbound's dual GIP/GLP-1 action appears more effective on average, but the right choice depends on your insurance coverage, tolerance, and your clinician's advice.
How much does Zepbound cost without insurance in 2026?
The list price is about $1,086 per month, but Lilly's self-pay vials cost roughly $299-$449 per month depending on dose. With commercial insurance coverage, the savings card can lower your copay to as little as $25 per month, and under a 2025 government agreement Medicare is set to cover Zepbound for obesity at about $50/month for eligible beneficiaries, rolling out in 2026. Confirm current pricing and your own coverage before starting.
What are the most common side effects of Zepbound?
Gastrointestinal effects are most common: nausea (roughly 25-30% of users in the pivotal trials), diarrhea, vomiting, and constipation, usually mild-to-moderate and worst during dose increases. Serious but rarer risks include pancreatitis, gallbladder problems, and kidney injury from dehydration. Tell your doctor about severe or persistent symptoms.
How is Zepbound dosed and injected?
It is a once-weekly injection under the skin (stomach, thigh, or upper arm). You start at 2.5 mg for 4 weeks, then increase by 2.5 mg no sooner than every 4 weeks as tolerated, up to a maximum of 15 mg weekly. Maintenance doses are 5, 10, or 15 mg. Follow your prescriber's specific instructions.
Who should not take Zepbound?
Avoid Zepbound if you or a family member has had medullary thyroid cancer (MTC) or MEN 2 syndrome, or if you have had a serious allergic reaction to tirzepatide. It is not recommended during pregnancy and is not approved for children. Use caution with a history of pancreatitis, gallbladder, or kidney disease, and discuss your full medical history with your doctor.
Will I regain the weight if I stop Zepbound?
Most people regain a significant portion of lost weight after stopping, because the appetite-suppressing effect ends when the medication does. Zepbound is generally intended as a long-term therapy, similar to medications for blood pressure or cholesterol. Do not stop on your own; discuss any changes with your doctor first.
Is Zepbound the same as Mounjaro?
Both contain the same active drug, tirzepatide, made by Eli Lilly. Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea, while Mounjaro is approved for type 2 diabetes. They are branded for different uses but share the same molecule.
Does Zepbound treat sleep apnea?
Yes. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication cleared for this use. In the SURMOUNT-OSA program it significantly reduced apnea-hypopnea events versus placebo, and it may be used with or instead of CPAP depending on your doctor's guidance.
Sources
- ZEPBOUND (tirzepatide) injection - Full Prescribing Information — DailyMed (U.S. National Library of Medicine) (2025)
- FDA Approves New Medication for Chronic Weight Management — U.S. Food and Drug Administration (2023)
- FDA Approves First Medication for Obstructive Sleep Apnea — U.S. Food and Drug Administration (2024)
- Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight — Eli Lilly and Company / New England Journal of Medicine (2022)
- Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine — Eli Lilly and Company / New England Journal of Medicine (2025)
- Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans — Eli Lilly and Company (2025)